Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTDM6HZ)

DTT Name Alpha-N-acetylglucosaminidase (NAGLU)
Synonyms UFHSD1; NAGLU; NAG; N-acetyl-alpha-glucosaminidase; Alpha-N-acetylglucosaminidase82 kDa form; Alpha-N-acetylglucosaminidase77 kDa form
Gene Name NAGLU
DTT Type
Successful target
 [1]
BioChemical Class
Glycosylase
UniProt ID
ANAG_HUMAN
TTD ID
T53103
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 3.2.1.50
Sequence
MEAVAVAAAVGVLLLAGAGGAAGDEAREAAAVRALVARLLGPGPAADFSVSVERALAAKP
GLDTYSLGGGGAARVRVRGSTGVAAAAGLHRYLRDFCGCHVAWSGSQLRLPRPLPAVPGE
LTEATPNRYRYYQNVCTQSYSFVWWDWARWEREIDWMALNGINLALAWSGQEAIWQRVYL
ALGLTQAEINEFFTGPAFLAWGRMGNLHTWDGPLPPSWHIKQLYLQHRVLDQMRSFGMTP
VLPAFAGHVPEAVTRVFPQVNVTKMGSWGHFNCSYSCSFLLAPEDPIFPIIGSLFLRELI
KEFGTDHIYGADTFNEMQPPSSEPSYLAAATTAVYEAMTAVDTEAVWLLQGWLFQHQPQF
WGPAQIRAVLGAVPRGRLLVLDLFAESQPVYTRTASFQGQPFIWCMLHNFGGNHGLFGAL
EAVNGGPEAARLFPNSTMVGTGMAPEGISQNEVVYSLMAELGWRKDPVPDLAAWVTSFAA
RRYGVSHPDAGAAWRLLLRSVYNCSGEACRGHNRSPLVRRPSLQMNTSIWYNRSDVFEAW
RLLLTSAPSLATSPAFRYDLLDLTRQAVQELVSLYYEEARSAYLSKELASLLRAGGVLAY
ELLPALDEVLASDSRFLLGSWLEQARAAAVSEAEADFYEQNSRYQLTLWGPEGNILDYAN
KQLAGLVANYYTPRWRLFLEALVDSVAQGIPFQQHQFDKNVFQLEQAFVLSKQRYPSQPR
GDTVDLAKKIFLKYYPRWVAGSW
Function Involved in the degradation of heparan sulfate.
KEGG Pathway
Glycosaminoglycan degradation (hsa00531 )
Metabolic pathways (hsa01100 )
Lysosome (hsa04142 )
Reactome Pathway
HS-GAG degradation (R-HSA-2024096 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
N-Acetyl-D-glucosamine DM1XBWR Autoimmune diabetes 5A10 Approved [1]
------------------------------------------------------------------------------------
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABO-101 DMUBLC3 Mucopolysaccharidosis 5C56.3 Phase 1/2 [2]
BMN 250 DMM25B1 Mucopolysaccharidosis type IIIB 5C56.3Y Phase 1/2 [3]
------------------------------------------------------------------------------------

The Drug-Metabolizing Enzyme (DME) Role of This DTT

DTT DME Name Alpha-N-acetylglucosaminidase (NAG) DME Info
Gene Name NAGLU
1 Approved Drug(s) Metabolized by This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Human calcitonin DM0WD1V N. A. N. A. Phase 4 [4]
------------------------------------------------------------------------------------

References

1 Development of bFGF-Chitosan Matrices and Their Interactions with Human Dermal Fibroblast Cells. J Biomater Sci Polym Ed. 2009;20(10):1335-51.
2 Clinical pipeline report, company report or official report of Abeona Therapeutics.
3 Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B. Drug Deliv Transl Res. 2020 Apr;10(2):425-439.
4 Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600.